Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2 - Wikidata - awgldk - TriplyDB

Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2

Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2

http://www.wikidata.org/entity/Q33521938

about

The clinical value of aberrant epigenetic changes of DNA damage repair genes in human cancer Stem Cell Hierarchy and Clonal Evolution in Acute Lymphoblastic Leukemia DNA mismatch repair system: repercussions in cellular homeostasis and relationship with aging Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers Chemoresistance and targeted therapies in ovarian and endometrial cancers Molecular Aspects of Head and Neck Cancer Therapy Drugging the Cancers Addicted to DNA Repair.DNA polymerases as potential therapeutic targets for cancers deficient in the DNA mismatch repair proteins MSH2 or MLH1 Drug-Repositioning Screens Identify Triamterene as a Selective Drug for the Treatment of DNA Mismatch Repair Deficient Cells Evolutionarily conserved genetic interactions with budding and fission yeast MutS identify orthologous relationships in mismatch repair-deficient cancer cells.DNA mismatch repair and oxidative DNA damage: implications for cancer biology and treatment.Retinal mitochondrial DNA mismatch repair in the development of diabetic retinopathy, and its continued progression after termination of hyperglycemia.Fusion of the Dhfr/Mtx and IR/MAR gene amplification methods produces a rapid and efficient method for stable recombinant protein production.Cytosine-based nucleoside analogs are selectively lethal to DNA mismatch repair-deficient tumour cells by enhancing levels of intracellular oxidative stress.A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol.Emerging tactical strategies for fighting the war on cancer based on the genetic landscape An inducible, isogenic cancer cell line system for targeting the state of mismatch repair deficiency.Drug therapy for hereditary cancers Variegated clonality and rapid emergence of new molecular lesions in xenografts of acute lymphoblastic leukemia are associated with drug resistance.Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications The role of folate metabolism in orofacial development and clefting.Ectopic expression of human MutS homologue 2 on renal carcinoma cells is induced by oxidative stress with interleukin-18 promotion via p38 mitogen-activated protein kinase (MAPK) and c-Jun N-terminal kinase (JNK) signaling pathways.Rethinking ovarian cancer: recommendations for improving outcomes.Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition.What is wrong with Fanconi anemia cells?Mismatch repair defects and Lynch syndrome: The role of the basic scientist in the battle against cancer DNA mismatch repair and the DNA damage response.Molecular dissection of microsatellite instable colorectal cancer New perspectives on molecular targeted therapy in ovarian clear cell carcinoma.Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target The role of personalized medicine in metastatic colorectal cancer: an evolving landscape.A Novel Chemotherapeutic Agent to Treat Tumors with DNA Mismatch Repair Deficiencies Screening of Pleural Mesotheliomas for DNA-damage Repair Players by Digital Gene Expression Analysis Can Enhance Clinical Management of Patients Receiving Platin-Based Chemotherapy.Methotrexate induces DNA damage and inhibits homologous recombination repair in choriocarcinoma cells.Recently identified and potential targets for colon cancer treatment.Genomic instability in breast and ovarian cancers: translation into clinical predictive biomarkers.The potential of exploiting DNA-repair defects for optimizing lung cancer treatment.Interrelationship between microsatellite instability and microRNA in gastrointestinal cancer.Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers.

P2860

Q26766285-BD1C09C0-D2D2-47F2-B8DC-E4539E27BF7F Q26799954-26EFA898-9B2C-47E1-85AF-14A8E9A27151 Q26995348-B28E33CC-9025-46CE-AC2E-9AA911E4F633 Q27006938-B28B362A-1549-4552-BF8C-2500FB38DBC7 Q28073246-94269EB6-A006-4A8F-B5DE-29E44FC02059 Q28082815-8C217C26-1A64-497F-8A8E-4E8C9E545D6A Q33702497-840D4971-5B3F-4531-A108-D2A2F395C5C5 Q33754229-3BE0D063-63AB-4246-A9DB-45A0A73116F1 Q33760331-23DD236C-5135-420F-905E-9D0AF90F5D11 Q34306599-448B6147-04E4-48C1-8300-713C8A32CAE5 Q34309933-328E72EE-6BAA-4D26-A53C-57FED21D7A08 Q34433611-D6B946FA-61BB-4BE8-AF29-76172FC5E993 Q34541494-E6D1FA79-72B4-4B9A-B5DC-1F85B3EF914D Q34567112-F246F4DA-8E90-4444-9011-7CD8AF022600 Q34995009-572D3E9D-81B9-4DEB-8105-8A00E75D87D1 Q35008971-8F78A36E-CC77-4CB8-9C8D-B93E65D2926C Q35036658-7206F0EA-841F-438E-B505-24F45D5851C7 Q35208929-21480763-3716-4C79-8D5B-E63190828F23 Q35467835-C2B0729B-C6CA-49B0-A14C-F891860D3E04 Q35836592-BCBC1EB8-ACD5-4792-BA95-C07B7C70628D Q35988387-E0FA9F8C-CEDB-45FE-AF94-F7F1F011563E Q36003744-5CAB254A-24C0-4830-A9CB-7F930A5EEC5B Q36050883-A2764127-4266-47D3-80FA-C2F9F489DEE7 Q36064946-8BF260E6-509A-4110-B25E-838A50E9B1D0 Q36144711-9C5F10D9-AB39-4C45-A708-9257CE7057A8 Q36186819-28F6B9A5-A721-4644-8E39-AE712945EC37 Q36540568-67D75549-D442-41D8-AA21-BF70F2817DC3 Q36540658-84060F14-6958-444D-A7E7-6A972972C504 Q36836733-F4058FFD-353C-4DAC-86EE-2C378AE56D13 Q36889642-B8B753CE-5CE4-47E6-B147-23D9F8D73DCA Q36990060-1752BE36-4955-4C6E-B7FD-BB196BA53F08 Q37130603-FC5203A6-5DD2-42F3-91FE-137D012B031A Q37276892-1F8BB2D5-32B7-4AEC-99E2-E77EFAB13209 Q37290519-A3485BB5-B50F-409E-9B64-7ADD35A71625 Q37429167-1F2BFA25-DFC0-42E6-A2AC-20EEE702B1FD Q37763104-31C13A90-7833-49B3-9710-8E7C570A6E71 Q37933098-ABBEFEAA-2F3E-4BCE-9C07-757487464B38 Q37983690-122E2E86-0655-4F17-8D0A-F819FB787410 Q38020473-77AED1B2-85F0-4779-B8BD-666DDCD02309 Q38087850-2E72159D-9B05-4E57-8F9D-55AF28224843

P2860

Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2

http://www.wikidata.org/entity/Q33521938

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

Methotrexate induces oxidative ...... DNA mismatch repair gene MSH2

@ast

Methotrexate induces oxidative ...... DNA mismatch repair gene MSH2

@en

Methotrexate induces oxidative ...... DNA mismatch repair gene MSH2.

@nl

type

label

Methotrexate induces oxidative ...... DNA mismatch repair gene MSH2

@ast

Methotrexate induces oxidative ...... DNA mismatch repair gene MSH2

@en

Methotrexate induces oxidative ...... DNA mismatch repair gene MSH2.

@nl

prefLabel

Methotrexate induces oxidative ...... DNA mismatch repair gene MSH2

@ast

Methotrexate induces oxidative ...... DNA mismatch repair gene MSH2

@en

Methotrexate induces oxidative ...... DNA mismatch repair gene MSH2.

@nl

P1433

Q33521938-2291E613-5662-408C-BDA9-4CCFEF35B637

P1476

Q33521938-4B1F2188-FB6E-4B78-BE10-5EC8E1DD3DD4

P2093

Q33521938-4F0F26B2-BCA3-4C56-B144-F02377C0C07C

Q33521938-51EB2282-AF3C-4112-8CF7-602B97754928

Q33521938-CBF5C620-AD64-492F-963E-B57B16928D10

P2860

Q33521938-0253C1BA-4EE3-437F-8E2C-CB29825D9561

Q33521938-07D41C61-E32B-46EF-8A34-5C0510308788

Q33521938-08B81554-9078-405A-ACD1-6059CC056FAB

Q33521938-099F2E64-697E-4A6B-83B8-6838B06C3886

Q33521938-0BAC6621-0763-4949-982B-AC20688CABFA

Q33521938-0EEB061F-F420-4349-9314-1724A38F27A8

Q33521938-1A016808-CD02-4942-B076-60BE054C7275

Q33521938-1D849E2B-6F3A-4D1F-9E94-B2C21239BFCF

Q33521938-1DF00600-2663-4967-A70E-70A657F0B289

Q33521938-2A4269A3-61D5-4082-9BB8-A12BF272BF35

P304

Q33521938-0DFCD93F-A1C1-4035-8FA7-D721634015BF

P31

Q33521938-AFEBB509-2897-48C2-A05F-17D079B3688B

P356

Q33521938-AFFD3638-7934-4CCE-8F74-EB282EBEBB67

P433

Q33521938-9F64F110-6CCE-4571-9551-2A749D7233F1

P478

Q33521938-02CC8D5A-CD81-43D1-B280-3D69DEBA39E7

P50

Q33521938-136A9330-7DB4-4019-9714-A7830DC35E5A

Q33521938-2BE176E3-A757-4A45-B37B-DC7E86568DBA

Q33521938-7ABB4E80-0AF7-4953-9435-A39F5F95C49D

Q33521938-C9CF8C79-B3BF-49A2-AAFC-D93E763A8E13

P577

Q33521938-3D3B10EF-4033-4430-A813-5289834FF992

P5875

Q33521938-EA8E857F-3F13-4D13-A3C1-6EBEEDAA7D72

P698

Q33521938-2322B5F7-D175-463B-A30F-D8725AB0E143

P921

Q33521938-7B1E0DC3-7071-4826-BF2A-D3435AEB0D82

P932

Q33521938-4E55F990-1D77-4663-9FCD-9643CA321F5F

P356

P1433

EMBO Molecular Medicine

P1476

Methotrexate induces oxidative ...... DNA mismatch repair gene MSH2

@en

P2093

Afshan McCarthy

http://www.w3.org/2001/XMLSchema#string

Sarah A Martin

http://www.w3.org/2001/XMLSchema#string

Suzanne Parry

http://www.w3.org/2001/XMLSchema#string

P2860

Mismatch repair participates in error-free processing of DNA interstrand crosslinks in human cells.

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

8-oxoguanine incorporation into DNA repeats in vitro and mismatch recognition by MutSalpha.

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

Mismatch repair and the hereditary non-polyposis colorectal cancer syndrome (HNPCC)

Anticancer antifolates: current status and future directions

Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer

The concept of synthetic lethality in the context of anticancer therapy

Probing tumor phenotypes using stable and regulated synthetic microRNA precursors

Isolation of MutSbeta from human cells and comparison of the mismatch repair specificities of MutSbeta and MutSalpha

P304

323-337

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/EMMM.200900040

http://www.w3.org/2001/XMLSchema#string

P433

6-7

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

Christopher J Lord

Darren J. Burgess

Louise J Barber

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40848600

http://www.w3.org/2001/XMLSchema#string

P698

20049736

http://www.w3.org/2001/XMLSchema#string

P921

P932

3378145

http://www.w3.org/2001/XMLSchema#string